IBM, ETH Zurich and CloudBroker team up to employ cloud-computing solutions that help researchers combat increasingly resistant bacteria.
IBM has announced that
researchers from science and technology university ETH Zurich
, a high-performance cloud-computing
company, have partnered with Big Blue to use cloud-computing technology to
conduct research focused on developing new antibiotics to fight disease.
According to the World
Health Organization, the number of antimicrobial-resistant pathogens is
increasing dramatically, threatening treatments to tuberculosis, malaria and
other now common illnesses caused by various bacteria. The study of bacterial
proteins has become increasingly important as understanding the complex
elements of bacteria can play a vital role in determining risks and determining
drugs that can fight resistant strands.
Using IBM's SmartCloud Enterprise
an enhanced queuing and data-management solution provided by CloudBroker,
researchers from ETH Zurich's Institute of Molecular Systems Biology were able
to identify nearly 250 potential virulence factors-or molecules that are secreted
by bacteria, viruses, fungi or protozoa and then multiply within humans-and
create nearly 2.3 million three-dimensional models with nearly 30,000
background data packets to study the function of these harmful, disease-causing
pathogens, IBM said.
Moreover, using the IBM
Smart Cloud Enterprise, the team had access to almost 250,000 computing hours on
a total of 1,000 parallel CPUs producing research on the structure of specific
proteins found in the streptococcus bacteria, which commonly causes strep
throat in humans.
"For our experiments,
we need very high capacity in short time frames," Dr. Lars Malmstrom, ETH
Zurich's lead researcher, said in a statement. "Cloud computing allows us to
reserve this computing capacity whenever researchers need it, and it is
available quickly. Research teams do not need to set it up or maintain it, and
thus can concentrate better on their research."
Rosetta, the open-source
software that predicts and designs protein structures, protein folding
mechanisms and protein-protein interactions, was also deployed on the cloud.
Through the use of these various technologies provided by IBM and CloudBroker,
researchers were able to analyze the massive amount of data within two weeks, a
task that would have taken several months without the use of IBM's cloud-computing
technologies, IBM officials said.
IBM has helped thousands of
clients adopt cloud models, and manages millions of cloud-based transactions
every day, the company said. IBM assists clients in areas as diverse as
banking, communications, health care and government to build their own clouds
or securely tap into IBM cloud-based business and infrastructure services. IBM
is unique in bringing together key cloud technologies, deep process knowledge,
a broad portfolio of cloud solutions and a network of global delivery centers. More information about IBM cloud solutions
CloudBroker GmbH, a startup
company based in Zurich, provides easy access to high-performance computing
applications in the cloud. CloudBroker was spun off from ETH
Zurich in 2008. It offers a platform to easily deploy scientific and technical
applications on cloud-computing infrastructures that are then ready to be used
immediately by researchers, with no additional time spent on installation or
configuration of the software. CloudBroker also takes care of user management,
testing and accounting of the software, allowing the users to just focus on
their research and development.
ETH Zurich-the Swiss
Federal Institute of Technology, Zurich-focuses on education, research and
applied results. The university has more than 16,000 students, including 3,500
doctoral candidates, from 80 countries. More than 400 professors teach and conduct
research in engineering, architecture, mathematics, natural sciences, system-oriented
sciences, and management and social sciences. ETH Zurich regularly appears at
the top of international rankings as one of the best universities in the world.
And 21 Nobel Laureates have studied, taught or conducted research at ETH